Novo Nordisk A/S $NVO Shares Acquired by Focus Partners Wealth

Focus Partners Wealth grew its position in Novo Nordisk A/S (NYSE:NVO) by 11.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 844,234 shares of the company’s stock after purchasing an additional 83,619 shares during the period. Focus Partners Wealth’s holdings in Novo Nordisk A/S were worth $43,105,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Quotient Wealth Partners LLC lifted its position in Novo Nordisk A/S by 2.0% during the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after acquiring an additional 177 shares in the last quarter. Certuity LLC lifted its position in Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares in the last quarter. Oakworth Capital Inc. lifted its position in Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after acquiring an additional 182 shares in the last quarter. True North Advisors LLC lifted its position in Novo Nordisk A/S by 3.9% during the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after acquiring an additional 199 shares in the last quarter. Finally, Asio Capital LLC lifted its position in Novo Nordisk A/S by 3.9% during the 4th quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after acquiring an additional 200 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NVO stock opened at $43.85 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $78.38. The stock’s 50 day moving average is $42.42 and its two-hundred day moving average is $45.98. The company has a market capitalization of $195.81 billion, a PE ratio of 10.29, a P/E/G ratio of 3.92 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Analysts predict that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.